Related Experiment Videos
A novel B-CLL specific nuclear protein (p44/46)
J Chruściel1, J Błonski, P Szymczyk
1Department of Cytobiochemistry, University of Lódź, Poland.
Insights
Researchers identified a specific 44/46 kDa nuclear protein in B cell chronic lymphocytic leukemia (B-CLL) and acute lymphoblastic leukemia (ALL) cells. This protein, absent in healthy cells, may indicate disease progression.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Protein expression profiles in mononuclear cells differ between B cell chronic lymphocytic leukemia (B-CLL) patients and healthy donors.
- Significant variations in nuclear protein electrophoretic patterns were noted, particularly between 37-52 kDa.
Purpose of the Study:
- To identify and characterize a specific nuclear protein antigen associated with B-CLL.
- To develop a diagnostic tool for B-CLL and related leukemias.
Main Methods:
- Electrophoresis was used to analyze protein fractions from mononuclear cells.
- Polyclonal antiserum was generated against a 44/46 kDa nuclear protein from B-CLL cells.
- Western blot analysis with alkaline phosphatase detected the target antigen.
Main Results:
- The generated antiserum specifically recognized a 44/46 kDa nuclear antigen in B-CLL and acute lymphoblastic leukemia (ALL) cells, but not in normal cells.
- No cross-reactivity was observed with T cell chronic lymphocytic leukemia (T-CLL) or non-leukemic tissues (stomach, colon).
- Higher expression of this antigen correlated with B-CLL progression.
Conclusions:
- A 44/46 kDa nuclear protein antigen is a potential biomarker for B-CLL and ALL.
- This antigen shows specificity for certain leukemic types and does not cross-react with normal tissues.
- The antigen's expression level may serve as an indicator of B-CLL disease progression.
Abstract:
Our previous results indicated some diversities in electrophoretic patterns of proteins from different cellular fractions, i.e. nuclear, mitochondrial, microsomal and cytosolic isolated from mononuclear cells from the peripheral blood of B cell chronic lymphocytic leukemia (B-CLL) patients and healthy donors. Major differences were observed in electrophoretic banding of nuclear proteins from normal and transformed cells, especially in molecular mass region of 37 52 kDa. Electrophoretically-specific nuclear protein with molecular mass of 44/46 kDa of cells originating from B-CLL patients was used for raising polyclonal antiserum. As it was determined by Western blot technique (with alkaline phosphatase) obtained antiserum recognized 44/46 kDa antigen of nuclear fraction from B-CLL and acute lymphoblastic leukemia (ALL) cells, but not from normal ones. Our preliminary data were revealed that this antiserum shows no crossreactivity with leukemic nuclear proteins of patients with T cell chronic lymphocytic leukemia (T-CLL) and neither with nuclear polypeptides from either normal or cancerous (adenocarcinoma) stomach and colon mucosa. Immunological analysis was shown that higher expression of this particular antigen seems to correlate with progression of B-CLL.